Ensysce Biosciences, Inc.

3:15 PM - 3:30 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Ensysce is a clinical stage biopharma company with a novel prodrug technology that, when applied to prescription medications, prevents abuse and overdose.

Our lead program PF614 uses this technology to make pain medication safer for patients and physicians. Approximately 30 people per day in the USA are dying by overdosing on opioids and endless more are abusing by chewing, injecting or snorting. They do this to immediately concentrate the ‘euphoria’ in the first minutes of taking the drug instead of the intended slower release. Our technology cannot be ‘cracked’ outside of the body because it only releases the active ingredient (oxycodone) after it mixes inside the gut with an enzyme (Trypsin), forcing a true 12-hour release. This is novel compared to the reformulated ADFs currently on the market.

Our Second technology (MPAR) for overdose prevention controls how much active ingredient will be released into the system at any one time if more than prescribed are ingested.
Company Type:
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2004
Main Therapeutic Focus:
Lead Product in Development:
PF614 Prodrug of oxycodone (ER)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3